Study reveals vaccine response in immunocompromised individuals
NCT ID NCT04780659
First seen Jan 11, 2026 · Last updated Jun 13, 2026 · Updated 25 times
Summary
This study measured immune responses after two doses of the Pfizer COVID-19 vaccine in 539 adults, including those with weakened immune systems (e.g., from organ transplant, HIV, or cancer treatment) and healthy individuals. Researchers analyzed blood and saliva samples to see how well the vaccine triggered antibody and cellular protection. The goal was to understand if the vaccine works as effectively in immunocompromised people as in healthy ones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska University Hospital
Stockholm, Huddinge, 14186, Sweden
Conditions
Explore the condition pages connected to this study.